Accelovance named finalist for Best Contract Research Organization at ViE Awards

Accelovance, a therapeutically focused contract research organization (CRO), has been named a finalist for "Best Contract Research Organization" at the upcoming Vaccine Industry Excellence (ViE) Awards hosted by the World Vaccine Congress.

This is the eighth consecutive year Accelovance has been honored as a finalist for the award, winning for "Best Contract Research Organization" in 2009, 2010, and 2011, and receiving a "Highly Recommended" distinction in 2013.

"We're excited to be a finalist for the 'Best Contract Research Organization' again at the World Vaccine Congress. Our eighth consecutive year receiving this nomination is a testament to the skill and knowledge of our employees, the relationships we have developed with our clients, and the difference our Sponsor partnerships have made within the field of vaccine development" commented Stephen J. Trevisan, Accelovance President and Chief Executive Officer.

Accelovance will be evaluated by an international panel for quality of services, performance, client satisfaction, Sponsor relationships, and the overall value brought to study Sponsors. Accelovance is well known within the industry for its experience in managing vaccine trials, for successful clinical oversight, patient enrollment and retention, and for providing full service solutions to Sponsors. Award winners will be announced at the 15th Annual World Vaccine Congress being held in Washington, D.C. April 7- 9, 2015.